An experimental drug cuts genetic heart disease risk by 94% in trial: What we know
Eli Lilly’s experimental drug, lepodisiran, reduces lipoprotein(a) (Lp[a]) levels by an average of 93.9 per cent in a ...
New drug may cut sudden heart risk by 94%
A new drug may help protect millions of people from heart attacks and strokes by lowering a little-known risk factor in the ...
Eli Lilly and Novo Nordisk are tackling heart health next
In this photo illustration, the injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April ...
The New York Times2d
Drug Reduces Mysterious Particle Involved in Heart Attack Risk
Mike Segar/Reuters Lp(a)-lowering “is a huge new frontier in cardiovascular medicine ... long favored for people with failing heart valves but no other symptoms. High blood pressure ...
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a genetically inherited risk ...